First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas-Reference-Cited by-同舟云学术

First-in-human phase I study of copanlisib (BAY 80-6946), an intravenous pan-class I phosphatidylinositol 3-kinase inhibitor, in patients with advanced solid tumors and non-Hodgkin's lymphomas

Published:2016-10 Issue:10 Volume:27 Page:1928-1940
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Patnaik A.,Appleman L.J.,Tolcher A.W.,Papadopoulos K.P.,Beeram M.,Rasco D.W.,Weiss G.J.,Sachdev J.C.,Chadha M.,Fulk M.,Ejadi S.,Mountz J.M.,Lotze M.T.,Toledo F.G.S.,Chu E.,Jeffers M.,Peña C.,Xia C.,Reif S.,Genvresse I.,Ramanathan R.K.

Funder

Bayer Pharma AG

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/27/10/1928/19446474/mdw282.pdf

Reference42 articles.

1. PI3K pathway alterations in cancer: variations on a theme;Yuan;Oncogene,2008

2. Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy;Ihle;Mol Cancer Ther,2009

3. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity;Saal;Proc Natl Acad Sci USA,2007